Table 4.
Disease characteristics and response (MRD or clinical) at the final response assessment in patients receiving G-B in cohort 1 of the GREEN study
| Factor, n/N (%) patients | MRD negativea (blood) | MRD negativea (bone marrow) | CR/Crib |
|---|---|---|---|
| All patients | 94/104 (90.4) | 44/65 (67.7) | 55/158 (34.8) |
| Binet stage A | 32/32 (100) | 13/18 (72.2) | 19/48 (39.6) |
| Binet stage B+C | 62/72 (86.1) | 31/47 (66.0) | 36/110 (32.7) |
| Disease bulk ≥5 cm | 57/64 (89.1) | 27/39 (69.2) | 29/95 (30.5) |
| ALC ≥50 × 109/l | 52/59 (88.1) | 25/38 (65.8) | 33/88 (37.5) |
| 17p deletion | 3/6 (50.0) | 2/3 (66.7) | 2/11 (18.2) |
| 11q deletion | 18/23 (78.3) | 5/15 (33.3) | 7/26 (26.9) |
| 12q trisomy | 18/20 (90.0) | 12/14 (85.7) | 8/26 (30.8) |
| 13q deletion | 32/32 (100) | 13/19 (68.4) | 22/52 (42.3) |
| CD38 positive | 49/55 (89.1) | 17/28 (60.7) | 22/70 (31.4) |
| CD38 negative | 37/41 (90.2) | 22/30 (73.3) | 22/59 (37.3) |
| ZAP70 positive | 54/60 (90.0) | 22/34 (64.7) | 30/82 (36.6) |
| ZAP70 negative | 32/36 (88.9) | 17/24 (70.8) | 14/47 (29.8) |
| IGHV mutated | 31/31 (100) | 12/17 (70.6) | 17/44 (38.6) |
| IGHV unmutated | 58/68 (85.3) | 28/44 (63.6) | 30/92 (32.6) |
ALC absolute lymphocyte count, CR complete response, CRi complete response with incomplete marrow recovery, G-B obinutuzumab plus bendamustine, IGHV immunoglobulin heavy variable chain, MRD minimal residual disease
a Patients with evaluable (laboratory sample with a valid result at the final response assessment) MRD
b Patients who achieved CR/CRi at the final response assessment in the intent-to-treat population